Caplin Point Laboratories Limited (CAPLIPOINT) — Corporate Action

📢 Key Event
Interim dividend of INR 4 per share approved with record date on May 30, 2026

🔄 What Changed
Net profit grew 20.1% YoY to ₹650 crores with 38.1% EBITDA margin and revenue up 13.2% YoY to ₹2,303 crores

🔮 What's Next
Targeted DMF filing by end of FY2027 for 90+ APIs, expansion into Canada, Australia, Mexico, and Brazil markets

💡 Investor Takeaway
Shareholders receive higher dividends while the company invests heavily in global market expansion and complex product development

Caplin Point Laboratories announced an interim dividend of INR 4 per share (200% payout) for FY26, with record date set for May 30, 2026, while reporting audited FY26 financials showing revenue of ₹2,303 crores, net profit of ₹650 crores, and a 38.1% EBITDA margin. The company highlighted strategic expansion into regulated markets including the US and Latin America, with ₹1000+ crores capex allocated for new facilities in Puducherry, Visakhapatnam, and Chennai focused on lyophilized injectables and oncology APIs. The audit confirmed compliance with SEBI regulations and Ind AS, and the company remains debt-free with strong cash flow.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CAPLIPOINT ✨ Ask AI About This